common side effects of avandia
headache
other side effects
edema
nausea
comprehensive list of adverse effects
reported adverse reports
upper respiratory tract infections
injury
headache
major adverse cardiovascular events
overall data from long-term rosiglitazone
active ingredient
avandia
trials
record
adopt
dream trials
rosiglitazone n
control n =-rrb-
difference in overall mortality
major adverse cardiovascular events
meta-analysis of shorter-term trials
risk for myocardial infarction with rosiglitazone
placebo
record trial
rosiglitazone
cardiac outcomes
regulation of glycemia in diabetes
significant difference in cardiovascular hospitalization
cardiovascular death
primary outcome
patients with type diabetes
receiving rosiglitazone
add-on therapy
n =-rrb-
active control
n =-rrb-
significant difference in the incidence of chf
secondary endpoint
patients
failed metformin
sulfonylurea monotherapy
age
years
male
following randomization
add-on rosiglitazone
active control
add-on metformin for those
sulfonylurea
add-on sulfonylurea for those
metformin
patients
target
glycosylated hemoglobin
hbac
heart failure
patients
receiving add-on rosiglitazone
patients
receiving active control
retrospective analysis of clinical trials
duration months
rosiglitazone
increased risk of myocardial ischemia
placebo control
events
angina pectoris
angina dyspnea
myocardial infarction
coronary thrombosis
myocardial ischemia
coronary artery disease
coronary artery disorder
increased risk with combination insulin therapy
patients
receiving nitrates for known coronary heart disease
cardiovascular events in patients with nyha class i
ii heart failure
increased risk of cardiovascular events
week trial in patients with nyha class i
ii heart failure
receiving rosiglitazone
n =-rrb-
placebo
n =-rrb-
events
cardiovascular deaths
worsening chf
worsening edema
worsening dyspnea
chf medication
cardiovascular hospitalization
edema
dose-related edema
rosiglitazone
clinical trials
patients
receiving rosiglitazone mg in combination with a sulfonylurea
incidence of edema
rosiglitazone monotherapy trials
edema
patients
dose
healthy volunteers
receiving rosiglitazone mg
weeks
significant increase in median plasma volume
placebo
concomitant administration with insulin
edema
higher frequency in the rosiglitazone
insulin combination trials
insulin
rosiglitazone with insulin
reports of new onset
exacerbation of chf
rate
insulin
mg
mg
insulin in combination with rosiglitazone
coadministration of rosiglitazone
insulin
edema
hypertension
frequency
cardiovascular deaths
congestive heart failure
chf
myocardial infarction
angina
angina pectoris
angina dyspnea
myocardial infarction
coronary thrombosis
myocardial ischemia
coronary artery disease
coronary artery disorder
anemia
patients
receiving rosiglitazone
active ingredient
avandia
monotherapy
combination therapy with metformin
sulfonylurea
metformin
sulfonylurea
incidence of anemia
laboratory findings
shown dose-related decreases in hemoglobin
hematocrit
decreases in hemoglobin
g/dl
hematocrit
changes
first months
following
dose increase
increased plasma volume
anemiafrequency
decrease in wbc counts
hyperbilirubinemia
alt elevationspostmarketing reports
hepatitis
hepatic enzyme elevations
times
upper limit of normal
hepatic failure
hyperglycemia
hypoglycemia
hypocholesterolemiauncommon
weight gainfrequency
increases in waist
hip circumference
mechanism of weight gain
combination of fluid retention
fat accumulation
adopt
monotherapy trial
median weight change at years
kg
frequency
resumption of ovulation in premenopausal
anovulatory women
hormonal imbalance
postmarketing reports
anaphylactic reaction
urticaria
angioedema
postmarketing reports
rash
pruritus
urticaria
angioedema
stevens-johnson syndrome
postmarketing reports
diabetic
macular edema
decreased visual acuity
upper
respiratory tract infection
sinusitisfrequency
dyspneapostmarketing reports
pulmonary edema
pleural effusions
painfrequency
fractures
long-term clinical trials
increased incidence of bone fracture in patients
receiving drug
glyburide
metformin
incidence
first year
trials
majority of fractures
women
upper arm
hand
foot
diarrhea
injury
fatigue
stomach pain
blurred vision
chest pain
discomfort
decrease in the amount of urine
dry mouth
flushed, dry skin
fruit-like breath odor
increased hunger
increased thirst
increased urination
irregular heartbeat
nausea
noisy, rattling breathing
pain in the shoulders
arms
jaw
neck
pale skin
unusual weight gain
sweating
swelling of the fingers
hands
feet
lower legs
trouble breathing
unexplained weight loss
unusual bleeding
bruising
unusual tiredness
weakness
vomiting
anxiety
chills
cold sweats
coma
confusion
dark urine
depression
dizziness
fast heartbeat
headache
loss of appetite
nightmares
seizures
shakiness
slurred speech
blue lips
fingernails
changes in vision
coughing
pink frothy sputum
hive-like swelling on the face
eyelids
lips
tongue
throat
hands
legs
feet
sex organs
itching
skin rash
light-colored stools
redness of the skin
yellow eyes
skin
ear congestion
fever
general feeling of discomfort
illness
hoarseness
other voice changes
injury
joint pain
muscle aches
pains
stuffy nose
shivering
sneezing
sore throat
trouble sleeping
back pain
cough
diarrhea
lightheadedness
pain
tenderness around the eyes
cheekbones